BioSyent Initiates First Dividend

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

MISSISSAUGA, Ontario, Oct. 12, 2022 (GLOBE NEWSWIRE) — BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that its Board of Directors has declared a quarterly dividend of $0.04 per common share, payable in Canadian Dollars on December 15, 2022, to shareholders of record at the close of business on November 30, 2022. This dividend qualifies as an ‘eligible dividend’ for Canadian income tax purposes. The declaration, timing, amount and payment of future dividends remain at the discretion of the Board of Directors.

About BioSyent Inc.

Listed on the TSX Venture Exchange under the trading symbol “RX”, BioSyent is a profitable growth-oriented specialty pharmaceutical company focused on in-licensing or acquiring innovative pharmaceutical and other healthcare products that have been successfully developed, are safe and effective, and have a proven track record of improving the lives of patients. BioSyent supports the healthcare professionals that treat these patients by marketing its products through its community, specialty and international business units.

As of the date of this press release, the Company has 12,145,861 common shares outstanding.

For a direct market quote for the TSX Venture Exchange and other Company financial information please visit www.tmxmoney.com.

For further information please contact:
Mr. René C. Goehrum
President and CEO
BioSyent Inc.
E-Mail: investors@biosyent.com
Phone: 905-206-0013
Web: www.biosyent.com

This press release may contain information or statements that are forward-looking. The contents herein represent our judgment, as at the release date, and are subject to risks and uncertainties that may cause actual results or outcomes to be materially different from the forward-looking information or statements. Potential risks may include, but are not limited to, those associated with clinical trials, product development, future revenue, operations, profitability and obtaining regulatory approvals.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.

Staff

Recent Posts

Vinamilk Showcases Science-Driven Innovation and Wins Prestigious Awards at Global Dairy Congress 2025

AMSTERDAM, June 26, 2025 /PRNewswire/ -- Vinamilk, Vietnam's leading dairy company, presented its science-driven innovation…

42 minutes ago

Tariff Uncertainty Disrupts Healthcare Operations: New Diagnostic Survey Highlights Staffing Changes, Delayed Purchases, and Supply Chain Strain

ARLINGTON, Va., June 26, 2025 /PRNewswire/ -- A new survey of 195 diagnostic imaging and…

7 hours ago

Ultima Genomics Selected to Support the World’s Largest Proteomics Studies to Date Led by Regeneron Genetics Center

FREMONT, Calif., June 26, 2025 /PRNewswire/ -- Ultima Genomics, a developer of an innovative new…

7 hours ago

Therap Enhances Secure Document Signing with Added ‘Order’ Module Search Option in Reference Module Dropdown

TORRINGTON, Conn., June 26, 2025 /PRNewswire/ -- Therap Services, the leading provider of HIPAA-compliant electronic documentation…

7 hours ago

Los Angeles Center for Ear, Nose, Throat and Allergy Introduces Clarity Technologies’ New Audiology Video Library

Cutting-edge tool aims to enhance patient education and experience while improving operational efficiency LOS ANGELES,…

7 hours ago